Private Advisor Group LLC Boosts Holdings in Danaher Corporation (NYSE:DHR)

Private Advisor Group LLC raised its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 4.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 50,365 shares of the conglomerate's stock after purchasing an additional 2,215 shares during the quarter. Private Advisor Group LLC's holdings in Danaher were worth $10,325,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the company. Fortis Capital Advisors LLC raised its position in Danaher by 1.3% during the fourth quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate's stock valued at $914,000 after buying an additional 50 shares during the period. Fayez Sarofim & Co grew its stake in Danaher by 0.6% in the fourth quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate's stock valued at $1,902,000 after purchasing an additional 50 shares in the last quarter. Coastal Bridge Advisors LLC grew its stake in Danaher by 4.8% in the fourth quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock valued at $252,000 after purchasing an additional 50 shares in the last quarter. Perennial Investment Advisors LLC grew its stake in Danaher by 2.2% in the fourth quarter. Perennial Investment Advisors LLC now owns 2,343 shares of the conglomerate's stock valued at $538,000 after purchasing an additional 51 shares in the last quarter. Finally, MGO One Seven LLC grew its stake in Danaher by 1.3% in the fourth quarter. MGO One Seven LLC now owns 4,285 shares of the conglomerate's stock valued at $984,000 after purchasing an additional 53 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Analysts Set New Price Targets

DHR has been the subject of several recent analyst reports. Guggenheim reiterated a "buy" rating and set a $250.00 price target on shares of Danaher in a research note on Wednesday, April 23rd. UBS Group decreased their target price on Danaher from $275.00 to $240.00 and set a "buy" rating for the company in a research note on Wednesday, April 23rd. Robert W. Baird increased their target price on Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research note on Friday. Wolfe Research decreased their target price on Danaher from $275.00 to $220.00 and set an "outperform" rating for the company in a research note on Monday, April 7th. Finally, Scotiabank upgraded Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price for the company in a research note on Friday, July 11th. Three analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $248.48.

Danaher Price Performance

Danaher stock opened at $189.98 on Friday. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $281.70. The company's 50 day moving average price is $196.13 and its two-hundred day moving average price is $205.03. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.31. The stock has a market cap of $135.96 billion, a P/E ratio of 36.89, a P/E/G ratio of 2.67 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.26. Danaher had a net margin of 15.81% and a return on equity of 10.80%. The firm had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.58 billion. On average, equities analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.67%. Danaher's dividend payout ratio is presently 24.85%.

Insider Buying and Selling at Danaher

In other news, Chairman Steven M. Rales sold 1,250,000 shares of the company's stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the transaction, the chairman directly owned 3,105,808 shares of the company's stock, valued at approximately $611,036,665.92. This represents a 28.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Christopher Paul Riley sold 15,805 shares of the business's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the transaction, the executive vice president owned 15,179 shares in the company, valued at $3,005,442. This represents a 51.01% decrease in their position. The disclosure for this sale can be found here. Insiders own 11.10% of the company's stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.